The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes according to treatment received for small node-negative HER2+ breast tumors in the Surveillance, Epidemiology, and End Results (SEER) database, 2010-2019.
 
Adrienne Gropper Waks
Consulting or Advisory Role - AstraZeneca
Research Funding - Genentech (Inst); MacroGenics (Inst); Merck (Inst)
 
Paolo Tarantino
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Lilly
 
Rachel A. Freedman
Employment - Firefly Health (I)
Stock and Other Ownership Interests - Firefly Health (I)
Research Funding - Eisai (Inst); Genentech/Roche (Inst); Puma Biotechnology (Inst)
 
Nancy U. Lin
Stock and Other Ownership Interests - Artera
Consulting or Advisory Role - Affinia Therapeutics; Aleta Biotherapeutics; Artera; AstraZeneca; Blueprint Medicines; Daiichi Sankyo; Denali Therapeutics; Johnson & Johnson/Janssen; Olema Pharmaceuticals; Pfizer; Prelude Therapeutics; Puma Biotechnology; Seagen; Voyager Therapeutics
Research Funding - Genentech (Inst); Merck (Inst); Olema Pharmaceuticals (Inst); Pfizer (Inst); Seagen (Inst); Zion Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Royalties for chapter in Up-to-Date regarding management of breast cancer brain metastases; Royalties, Jones & Bartlett
 
Nabihah Tayob
No Relationships to Disclose
 
Carlos Teodoro Vallejo
No Relationships to Disclose
 
Julieta Leone
No Relationships to Disclose
 
Sara M. Tolaney
Consulting or Advisory Role - 4D Pharma; AstraZeneca; Athenex; BeyondSpring Pharmaceuticals; Blueprint Medicines; Bristol-Myers Squibb; Certara Inc; Chugai Pharma; CytomX Therapeutics; Daiichi Sankyo; Eisai; Ellipses Pharma; G1 Therapeutics; Genentech; Immunomedics/Gilead; Infinity Pharmaceuticals; Kyowa Hakko Kirin; Lilly; Merck; Mersana; NanoString Technologies; Nektar; Novartis; Odonate Therapeutics; OncoPep; OncoSec; OncXerna Therapeutics; Paxman; Pfizer; Puma Biotechnology; Reveal Genomics; Samsung Bioepis; Sanofi; Seagen; Zentalis; Zymeworks
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cyclacel (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); NanoString Technologies (Inst); Nektar (Inst); Novartis (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst)
 
Jose Pablo Leone
Consulting or Advisory Role - Minerva Biotechnologies
Research Funding - Kazia Therapeutics (Inst); Seagen (Inst)